Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/ENP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Did you miss the PeerView DLBCL Seminar & Tumor Board at the Annual Hematology Meeting in New Orleans or want to revisit this important educational event? Access this program to watch a panel of experts debate the emergence of potent, antibody-based treatment platforms for patients with DLBCL, including novel CD19-directed antibodies, antibody-drug conjugates, and CD3xCD20 bispecific agents. These discussions are paired with case scenarios offering guidance on how to integrate these platforms into personalized management for DLBCL patients. The panel also explores the identification of candidates for treatment with novel antibodies; therapeutic sequencing and bridging strategies; and appropriate safety management and monitoring. Don’t miss this informative video to receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated evidence and guideline recommendations surrounding the incorporation of CD19, CD79, and CD3/CD20 targeting antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Integrate novel antibody-based treatment platforms into treatment plans for patients with DLBCL, including as sequential therapy over multiple lines of treatment, for patients unable to receive transplant, or in conjunction with cytotoxic regimens; and Develop team-based plans to manage practical safety and dosing considerations related to antibody therapy, including for patients with R/R DLBCL receiving active treatment.